parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in podocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	6 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 6265

receipt 6274: TJP1 in dopamine neurons, braak

power: full sample +0.34 (p 0.164, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.34 (p 0.164, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.173, n 18). could be the mix.
skeptic: leave-one-out range +0.26 to +0.46, sign flips 0; without severely affected donors +0.34 (p 0.164, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TJP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6273: TJP1 in oligodendrocytes, braak

power: full sample +0.24 (p 0.337, n 18), 95% CI -0.26 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.20 (p 0.429, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
skeptic: leave-one-out range +0.14 to +0.35, sign flips 0; without severely affected donors +0.24 (p 0.337, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TJP1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts